Online magazine Money has published an article by Stuart Bromley highlighting the investment opportunity with LTR Pharma, as it progresses the development of SPONTAN nasal spray for the treatment of Erectile Dysfunction (ED).
Here’s excerpt:
“While most current treatments are off patent and generic, making them quite cheap, it is believed that many consumers looking for ED solutions are less concerned about the price and more so about the efficacy, speed, and safety of the product, with Spontan seemingly delivering strongly on these measures.
Should they gain approval, the growth in online sales is also an exciting prospect which is expected to bring stronger margins, while also providing consumers with a more convenient experience.”